Navigation Links
Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
Date:5/21/2008

to what we predicted based on extensive lab testing of JX-594. This peer-reviewed publication in a Lancet journal represents a major advance for JX-594 and the rest of our pipeline," said David Kirn, M.D., President & CEO of Jennerex. "We especially want to express our extreme gratitude to the doctors, the patients and their families, and our partners at Green Cross who have all pioneered this treatment with us."

Dr. B. G. Rhee, Executive Vice President, Corporate Development at Green Cross, said "Based on these promising clinical results with our partners at Jennerex, we are in the process of opening the Phase II liver cancer trial at world-renowned liver cancer hospitals in South Korea." Jennerex collaborated closely with medical and scientific research teams in South Korea at Dong-A University and Pusan National University Hospitals, and at the Ottawa Health Research Institute, Ottawa, Canada.

Phase I-II Liver Cancer Study

As reported in the Lancet Oncology publication, 14 patients with a variety of treatment-refractory cancer types (e.g. liver, colon, lung) in the liver were treated every three weeks with JX-594 by ultrasound-guided intratumoral injection. Patients had advanced cancers that had failed all available therapies and were therefore considered terminal. Treatment was well-tolerated during dose-escalation up to the maximum-tolerated dose, with the expected mild to moderate flu-like symptoms; no severe toxicities due to treatment were reported up to these doses. Cancer destruction and objective evidence for efficacy were reported in the majority of patients, including all three with primary liver cancer and patients with lung and colon cancers. Tumor responses were achieved in evaluable patients by objective criteria including RECIST (Response Evaluation Criteria in Solid Tumor) (response in 30 percent of patients, stable disease in 60 percent of patients) and Choi criteria (response in 80% of patients). Tumor responses were associ
'/>"/>

SOURCE Jennerex
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
4. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
5. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
6. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
7. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
8. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
9. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
10. Promising Cystic Fibrosis Compound on Track for Development
11. Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Research and Markets ... of the "Global Gynecological Devices Market ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... wide categories based on their operations. These ... different gynecological conditions that affect the female ...
(Date:9/19/2014)... TRIANGLE PARK, N.C. , Sept. 19, 2014 ... focused on cloud-based drug design and development, partnering ... The company,s mission is to design new drugs ... 1 and 2 partners to further their development. ... its portfolio investments. To support this business model, ...
(Date:9/19/2014)... , Sept. 19, 2014 The American Association ... Medical Design and Manufacturing has joined the AAHomecare Corporate ... Harvey Diamond have been actively involved in ... as it has quickly grown into a major global ... like Drive allows AAHomecare to increase efforts on behalf ...
Breaking Medicine Technology:Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2
... Inc. (NASDAQ: DCTH ) announced today that management ... Conference on Tuesday, August 16, 2011 at 2:25 P.M. ET ... an overview of the Company,s business strategy and recent corporate ... invitation only. Delcath will offer a live audio webcast of ...
... 10, 2011 Leading events organizers UBM Canon ... (LSE: UBM), today announced a virtual conference event which will examine ... chain, counterfeit drugs. Titled ,Pharmaceutical Track & Trace Authentication: The Fight ... from 6:00 to 14:00 New York time, 12:00 to 20:00 Paris ...
Cached Medicine Technology:Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011 2Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011 3UBM Canon Introduces a Compelling New Virtual Conference Focused on Track & Trace Solutions for the Pharma Sector 2UBM Canon Introduces a Compelling New Virtual Conference Focused on Track & Trace Solutions for the Pharma Sector 3
(Date:9/19/2014)... September 19, 2014 Lipitor lawsuits ( ... some patients to develop Type 2 diabetes continue to ... in U.S. District Court, District of South Carolina, Bernstein ... on September 12, 2014, discovery is underway and moving ... noted that Pfizer, Inc., the manufacturer of Lipitor, has ...
(Date:9/19/2014)... In partnership with Raw Beauty NYC, OC healthcare ... project’s social media efforts. StudioPMG is honored to be a ... of beauty as it applies to disabled women. , ... Baer and Vanessa Silberman, who wanted to create a photo ... Dixon, Wendy Crawford, Susan Solman and Sabrina Cohen later joined ...
(Date:9/19/2014)... campus of Mayo Clinic have discovered a defect in ... overproduction of toxic protein in the brains of ... communication between neurons both significant contributors to this ... issue of Neuron , offers the ... rejuvenate or rescue this pathway," says the study,s lead ...
(Date:9/19/2014)... 2014 (HealthDay News) -- More states are passing legislation ... to use for any child having a severe allergic ... "anaphylaxis," an allergic reaction that can lead to throat ... and even death. In people with severe ... nuts, insect venom or certain drugs, anaphylaxis can occur ...
(Date:9/19/2014)... difficult to study with X-ray crystallography, not least because ... crystallize, but also because their very nature means they ... structure can be obtained it is often of low ... domains that sometimes create more puzzles than they solve. ... D70, 2241-2255; doi: 10.1107/S1399004714016496 ] , Now, Gunnar ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:OC Healthcare Agency StudioPMG Partners with The Raw Beauty Project ™ NYC 2014 2Health News:Mayo researchers reveal pathway that contributes to Alzheimer's disease 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 3Health News:A refined approach to proteins at low resolution 2Health News:A refined approach to proteins at low resolution 3
... soon connect every nook and corner of its vast ... social services to people, especially those living in far-flung ... of EDUSAT is being expanded across the country while ... the Indian Space Research Organisation (ISRO)," said S. Krishnamurthy, ...
... taken one more step towards a successful womb transplant. // ... wombs removed and then reconnected, Swedish scientists say. ... transplant in the sheep - where the same womb is ... that half the sheep in the study developed fatal complications ...
... Haryana government Tuesday proposed a medical university in the state ... ,Addressing the silver jubilee celebrations of the Government Dental ... Hooda said that setting up a medical university would help ... ,Hooda said that paucity of funds would ...
... researchers, children who report in with a head injury are twice ... //with children who sprain their ankle or wrist, instead. , ... which was published in the journal Pediatrics: “They were almost twice ... kids who had a sprained ankle or wrist." , ...
... Seventy percent of pediatricians rely on patients' family members ... a study by Johns Hopkins School of Medicine, the ... author Dennis Kuo, a general pediatrics fellow at Johns ... from the American Academy of Pediatrics and found that ...
... risk of breast cancer if they eat red meat, one more study ... of red meat had a 56% increased risk compared with those who ... meat, such as bacon, sausages, ham or pies, had a 64% greater ... University of Leeds study features in the British Journal of Cancer. ...
Cached Medicine News:Health News:Satellites Set to Play Good Samaritans in India 2Health News:Satellites Set to Play Good Samaritans in India 3Health News:Womb Transplant Pregnancy Success 2Health News:When ‘Humpty Dumpty’ Falls Aga 2Health News:Red Meat Increases Breast Cancer Risk 2
Sprint Quattro Secure™ is a Steroid-Eluting, True Bipolar, Active Fixation ICD Lead....
The Livewire steerable electrophysiology catheter is uniquely designed with an ergonomic handle and patented steering mechanism to provide smooth, precise catheter tip movement, even during lengthy e...
The Livewire cannulator offers improved access to the coronary sinus by combining the ergonomic Livewire steering mechanism with numerous specialized features....
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
Medicine Products: